logo
Share SHARE
FONT-SIZE Plus   Neg

FDA Seeks Addl Information To Complete Review Of HyQ BLA - Quick Facts

Baxter International Inc. (BAX) and Halozyme Therapeutics Inc. (HALO) announced that the U.S. Food and Drug Administration is requesting additional information to complete its review of the HyQ Biologics License Application or BLA.

Baxter and Halozyme said that they will work closely together to develop studies to provide additional data to address concerns raised by the FDA related to the long-term chronic use of HyQ. The companies now expect to participate in a meeting of the FDA's Blood Products Advisory Committee concerning the agency's request for additional data.

The companies expect these requests to require additional time to complete and to delay the companies' anticipated regulatory review and approval timeline.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Heading into a quiet week that precedes the final FOMC meeting of the year, the economic momentum remains strong. Data releases from the just concluded week makes it tough for the central bank to pass up an interest rate hike. However, will the Fed risk a backlash in a transition period on the political... AutoZone, Inc., an automotive replacement parts retailer, reported Tuesday higher profit in its first quarter with increased net sales and domestic store sales. Earnings per share topped analysts' estimates, while top line missed the view. In the pre-market activity on the NYSE, AutoZone shares were gaining 1.10 percent. The Justice Department, in the antitrust trial against the proposed Aetna- Humana Merger, argued that the merger would harm senior citizens who buy private Medicare plans. The U.S. Department of Justice stated that the merger would also harm consumers who buy plans on Affordable Care Act marketplaces, reports said. However, healthcare insurers Aetna And Humana defended their proposed merger..
comments powered by Disqus
Follow RTT